We thus speculated on the predictive role of anthropometric indicators of general adiposity, i.e., body mass index (BMI), and circulating biomarkers of glucose metabolism, i.e., fasting glucose, on treatment outcomes and verified the stated hypothesis in an observational, multicentre study of HR + HER2- advanced breast cancer patients treated with everolimus and exemestane in first and subsequent lines of therapy (the EverExt study). Here, ERBB2 is linked to breast carcinoma.